Skip to main content
💬 #ACR2025 Topic Panels — LIVE!
Nov. 2 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumat

Dr. John Cush RheumNow

11 months ago
💬 #ACR2025 Topic Panels — LIVE! Nov. 2 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: 👉 PsA Join Us Live on: X Live • Facebook Live • YouTube Live • LinkedIn Live • https://t.co/V10S4oVFsv Top experts. Real clinical insight. Don't miss https://t.co/A4pUjZG3Dr
Upadacitinib is a Double Edged Vascular Sword in GCA

Dr. David Liew discusses abstracts O751, O738, and O734 presented

Dr. John Cush RheumNow

11 months ago
Upadacitinib is a Double Edged Vascular Sword in GCA Dr. David Liew discusses abstracts O751, O738, and O734 presented at #ACR25. https://t.co/eTmVehP2Cd https://t.co/vxehwRWM2D
Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty.  Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!
Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our articles, videos and podcasts.
Hospitalization in Stills: Is it "Still" an infection?

Dr. Janet Pope discusses abstract 0163, "Trends in hospitalizat

Dr. John Cush RheumNow

11 months ago
Hospitalization in Stills: Is it "Still" an infection? Dr. Janet Pope discusses abstract 0163, "Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)," https://t.co/3Z0U9XN3nx
Rheumatoid arthritis and the ‘big bang’ at #ACR25!

Is there ‘bang for the buck’ using big data to help predic

Dr. John Cush RheumNow

11 months ago
Rheumatoid arthritis and the ‘big bang’ at #ACR25! Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA? https://t.co/QDvdiP3q9R https://t.co/cz4j4vZkSd
SLE Conference Preview: progress in biologics at #ACR25

We now have four licensed targeted therapies (i.e., belimumab,

Dr. John Cush RheumNow

11 months ago
SLE Conference Preview: progress in biologics at #ACR25 We now have four licensed targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis and belimumab and anifrolumab for active non-renal SLE). What are other issues to be addressed and https://t.co/uvVICAsCzo
AI Scribes Found their Favorite Doctors

Dr. Aurelie Najm discusses abstract 0189, "“Try it, you’ll love it”: Pat

Dr. John Cush RheumNow

11 months ago
AI Scribes Found their Favorite Doctors Dr. Aurelie Najm discusses abstract 0189, "“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists", presented at #ACR25 https://t.co/QTYFvLa95Y https://t.co/ZIvMovloBL
Every year I love the late breaking abstracts. It’s consistently my favourite part of the meeting program, by some distance. Here's why you should love them, too.
Rheum Now Rheumatology Round-Up — LIVE
Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheu

Dr. John Cush RheumNow

11 months ago
Rheum Now Rheumatology Round-Up — LIVE Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25. 📡 Live https://t.co/ZwP4UwojuZ
Sexual Function in axSpA
×